Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 52

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 52
---
 period ended 2024. The decrease in cash used in operating activities is primarily attributable to decreased operating expenses incurred by the Company during the nine months ended June 30, 2025 as compared to the same period ended 2024.

Financing Activities

Net cash generated by financing activities for the nine months ended June 30, 2025 was $242,545 which consisted of proceeds from notes payables.

Liquidity & Capital Resources Outlook

As of June 30, 2025, the Company had cash of $ 1,761 and net working deficit of approximately $5.8 million.

The Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and it has incurred and expects to continue incur significant research & development cost for products development.

The accompanying financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. As of June 30, 2025, the Company had cash of approximately $1,761 and an accumulated deficit of approximately $21 million. The Company has incurred recurring losses, experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. Without additional funding, there is substantial doubt about the Company’s ability to continue as a going concern for the twelve months from the date of these financial statements.

<div align='center'>38</div>

Contractual Obligations

As of June 30, 2025 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Exchange Act.

Three Months and Six Months Ended March 31, 2025

Results of Operations

Three months and six months ended March 31, 2025 and 2024

Revenues

Revenues from continuing operations were $59,065 for the three months ended March 31, 2025 and $59,064 for the same period ended 2024. $27,425 of revenue from related parties recognized during the three months ended March 31 2025 and consisted of anniversary expense receivable pursuant to a license granted by the Company to